A Phase 3 22-week Multi-center Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.